Dr Thomas Pembroke

2023

• Pembroke, T. P. I. et al. 2023. Rising incidence, progression and changing patterns of liver disease in Wales 1999-2019. World Journal of Hepatology 15(1), pp. 89-106. (10.4254/wjh.v15.i1.89)

2020

• Sebastiani, G. et al. 2020. Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV‐monoinfected patients. HIV Medicine 21(2), pp. 96-108. (10.1111/hiv.12799)

2019

• Benmassaoud, A. et al. 2019. Liver-related events in HIV-infected persons with occult cirrhosis. Clinical Infectious Diseases 69(8), pp. 1422-1430. (10.1093/cid/ciy1082)
• Appanna, G. D., Pembroke, T. P. I., Miners, K. L., Price, D. A., Gallimore, A. M., Ladell, K. and Godkin, A. J. 2019. Rituximab depletion of intrahepatic B cells to control refractory hepatic autoimmune overlap syndrome. QJM: An International Journal of Medicine 112(10), pp. 793-795. (10.1093/qjmed/hcz161)

2018

• Pembroke, T. and Sebastiani, G. 2018. Non-invasive Serum Markers of Fibrosis. In: Berzigotti, A. and Bosch, J. eds. Diagnostic Methods for Cirrhosis and Portal Hypertension. Springer, pp. 63-82., (10.1007/978-3-319-72628-1_5)

2017

• Pembroke, T. et al. 2017. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. Journal of Hepatology 67(4), pp. 801-808. (10.1016/j.jhep.2017.05.011)
• Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
• Pembroke, T. and Sebastiani, G. 2017. Hepatic steatosis, hepatitis C, and human immunodeficiency viruses: A complex interplay. Hepatology 66(2), pp. 673-674. (10.1002/hep.29218)

2016

• Pembroke, T. and Raj, L. S. 2016. Fibrofatty Band-Associated Small Bowel Obstruction After Marathon Running. ACG Case Reports Journal 3(1), pp. e145. (10.14309/crj.2016.118)

2014

• Pembroke, T. 2014. Natural Killer cell activation and evasion during chronic hepatitis C virus infection. PhD Thesis, Cardiff University.

2013

• Scurr, M. et al. 2013. Escalating regulation of 5T4-specific IFN- + CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunology Research 1(6), article number: 416. (10.1158/2326-6066.CIR-13-0035)
• Pembroke, T., Gallimore, A. and Godkin, A. 2013. Flow cytometry makes all the difference. Journal of Hepatology 59(4), pp. 909-910. (10.1016/j.jhep.2013.05.047)
• Pembroke, T., Christian, A., Jones, E., Hills, R. K., Wang, E. C. Y., Gallimore, A. M. and Godkin, A. J. 2013. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon treatment. Gut n/a (10.1136/gutjnl-2013-304472)

2012

• Pembroke, T. et al. 2012. Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+T-cell immunity. European Journal of Immunology 42(9), pp. 2383-2394. (10.1002/eji.201142072)
• Pembroke, T., Wang, E. C. Y., Gallimore, A. M. and Godkin, A. J. 2012. PMO-174 Intrahepatic natural killer cell phenotyping and functional analysis by fine needle aspiration in chronic HCV infection. Gut 61(S2), pp. A144-A145. (10.1136/gutjnl-2012-302514b.174)

2006

• Pembroke, T. P. I., Rasul, F., Hart, C. L., Smith, G. D. and Stansfeld, S. A. 2006. Psychological distress and chronic obstructive pulmonary disease in the Renfrew and Paisley (MIDSPAN) study. Journal of Epidemiology and Community Health 60(9), pp. 789-792. (10.1136/jech.2005.042150)